Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anergis SA

www.anergis.ch

Latest From Anergis SA

Pipeline Watch: Phase III Readouts For Gilenya, Duvelisib, Trimbow

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Watch: Top-Line Phase III Canakinumab, Shingrix And Brolucizumab Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Watch: Phase III Readouts For Guselkumab, Volanesorsen And Dupilumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Gloom Is Overblown: Allergy Vaccine Sector Is Poised To Globalize

The failure of Circassia’s cat allergy vaccine product in a Phase III study, and other recent setbacks including a one-year delay to Allergy Therapeutics’ US ambitions, have not stymied the excitement in a sector that promises new approaches to grass, tree, peanut and other food allergies, and much more convenient treatment regimens.

Commercial Market Intelligence
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Immune Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Anergis SA
  • Senior Management
  • Vincent Charlon, PhD, CEO
    Zoltàn Czigler, CFO
    Christophe Reymond, PhD, CSO
  • Contact Info
  • Anergis SA
    Phone: 21 651 92 20
    Route de la Corniche 9B
    Biopôle III
    Epalinges, CH-1066
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register